Genevant Sciences

nucleic acid delivery

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development headed by the team that enabled delivery for the world’s only approved small interfering RNA (siRNA)-LNP product, and an innovative culture that positions us to maintain our leadership for years to come.